Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naive Adults Without Baseline Genotyping Test (D2ARLING Study)
Latest Information Update: 12 Nov 2024
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms D2ARLING
Most Recent Events
- 07 Nov 2024 According to ViiV Healthcare media release, data from the study will be presented at HIV Glasgow 2024, being held in Glasgow, Scotland from 10 -13 November 2024.
- 19 Feb 2024 Planned End Date changed from 1 Sep 2023 to 30 Sep 2023.
- 19 Feb 2024 Planned primary completion date changed from 1 Sep 2023 to 30 Sep 2023.